Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
RNN [AMEX]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.06 Insider Own4.20% Shs Outstand176.51M Perf Week-15.52%
Market Cap172.98M Forward P/E- EPS next Y-0.08 Insider Trans- Shs Float153.30M Perf Month-24.62%
Income-6.80M PEG- EPS next Q-0.02 Inst Own6.60% Short Float6.96% Perf Quarter-12.50%
Sales- P/S- EPS this Y50.00% Inst Trans173.33% Short Ratio1.24 Perf Half Y100.00%
Book/sh0.08 P/B12.25 EPS next Y0.00% ROA-49.00% Target Price2.83 Perf Year226.67%
Cash/sh0.08 P/C11.53 EPS next 5Y- ROE-81.70% 52W Range0.28 - 1.85 Perf YTD92.16%
Dividend- P/FCF- EPS past 5Y7.80% ROI- 52W High-47.03% Beta1.40
Dividend %- Quick Ratio19.40 Sales past 5Y- Gross Margin- 52W Low250.00% ATR0.11
Employees16 Current Ratio19.40 Sales Q/Q- Oper. Margin- RSI (14)38.61 Volatility15.02% 9.88%
OptionableNo Debt/Eq0.00 EPS Q/Q33.30% Profit Margin- Rel Volume0.23 Prev Close0.96
ShortableYes LT Debt/Eq0.00 EarningsNov 04 Payout- Avg Volume8.59M Price0.98
Recom2.00 SMA20-15.37% SMA50-18.28% SMA20038.90% Volume1,961,086 Change2.08%
28-Dec-12Initiated Burrill Institutional Research Mkt Outperform $1
18-Jan-12Resumed Rodman & Renshaw Mkt Perform
16-Jun-11Resumed Brean Murray Buy $3
02-Dec-10Initiated Brean Murray Buy $3
02-Apr-14 09:00AM  Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for Clinical Research Annual Meeting Business Wire +12.28%
27-Mar-14 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
24-Mar-14 08:15AM  Rexahn sees complete RX-3117 Phase I enrollment in 4Q14-early FY15 theflyonthewall.com
08:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights Business Wire
21-Mar-14 04:19PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report EDGAR Online
19-Mar-14 06:00AM  3 Stocks Under $10 Making Big Moves at TheStreet
17-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York Business Wire
15-Mar-14 03:15PM  This Week in Biotech: NW Bio Soars While Geron Goes Geronimo at Motley Fool
12-Mar-14 04:30PM  Phase I Data on Rexahn's Supinoxin Zacks
04:30PM  Phase I Data on Rexahn's Supinoxin
11-Mar-14 02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher at Motley Fool
02:59PM  Why Rexahn Pharmaceuticals Inc. Jumped Higher
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors Business Wire
08:00AM  Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors
07-Mar-14 10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet -8.33%
10:49AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
06:00AM  Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine at TheStreet
04-Mar-14 08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference Business Wire
08:00AM  Rexahn Pharmaceuticals to Present at the 26th Annual ROTH Conference
03-Mar-14 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Optionetics +5.19%
04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors Business Wire
08:00AM  Rexahn Pharmaceuticals Appoints Mark Carthy to Board of Directors
27-Feb-14 12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket at Seeking Alpha +10.66%
12:14PM  Rexahn Pharmaceuticals: Another $1.30 Biotech Lottery Ticket
06-Feb-14 03:15PM  5 Stocks Under $10 Set to Soar at TheStreet +7.77%
04-Feb-14 08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Business Wire
08:00AM  Rexahn Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
31-Jan-14 02:16PM  Following Unmet Needs To Biotech Profits: Echo He at Seeking Alpha
02:16PM  Following Unmet Needs To Biotech Profits: Echo He
27-Jan-14 02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3% Zacks
02:11AM  Rexahn Pharmaceuticals (RNN) Jumps: Stock Up 5.3%
21-Jan-14 04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 at TheStreet
07:00AM  It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
15-Jan-14 03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility at Seeking Alpha -10.34%
03:38PM  Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
09:06AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
08:59AM  Rexahn Announces $20 Million Registered Direct Offering Business Wire
08:59AM  Rexahn Announces $20 Million Registered Direct Offering
08:26AM  3 Biotechs Getting Plenty Of Attention From Investors at Seeking Alpha
14-Jan-14 09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma Business Wire -27.50%
09:00AM  Rexahn Initiates Phase IIa Clinical Trial of Archexin┬« in Patients with Metastatic Renal Cell Carcinoma
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
08:53AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
10-Jan-14 10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today at TheStreet +62.86%
10:35AM  Why Rexahn Pharmaceuticals (RNN) Is Up Today
09-Jan-14 04:20PM  Rexahn Pharma rises as analyst starts coverage AP +12.90%
04:20PM  Rexahn Pharma rises as analyst starts coverage
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial at Seeking Alpha
12:20PM  Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial
08-Jan-14 08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors Business Wire +5.08%
08:00AM  Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors
07-Jan-14 08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 Business Wire +5.36%
08:00AM  Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014
22-Dec-13 12:49PM  Rexahn: A Turn Around Story For 2014 at Seeking Alpha
12:49PM  Rexahn: A Turn Around Story For 2014
11-Dec-13 08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902) Business Wire +20.00%
08:00AM  Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin TM (RX-5902)
25-Nov-13 01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment at Seeking Alpha +5.26%
01:47PM  Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment
20-Nov-13 01:05PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
01:05PM  REXAHN PHARMACEUTICALS, INC. Financials
19-Nov-13 08:00AM  Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit Business Wire
14-Nov-13 08:00AM  Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update Business Wire
13-Nov-13 04:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online +10.53%
16-Oct-13 04:31PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
11-Oct-13 09:02AM  InPlay: Rexahn Pharmaceuticals announced it has received commitments from certain institutional investors to purchase an aggregate of $5.3 million of Rexahn's securities in an at market registered direct offering Briefing.com -5.66%
09:00AM  Rexahn Announces $5.3 Million At Market Registered Direct Offering Business Wire
10-Oct-13 08:29AM  Rexahn signs exclusive license agreement for Lipid-Coated Albumin Nanoparticle theflyonthewall.com
08:01AM  InPlay: Rexahn Pharmaceuticals in-licenses novel oligonucleotide targeted drug delivery platform from Ohio State University Briefing.com
08:00AM  Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University Business Wire
06-Oct-13 08:57PM  Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill at Seeking Alpha
03-Oct-13 02:28PM  5 Stocks Under $10 Set to Soar at TheStreet +6.25%
30-Sep-13 08:13AM  Rexahn announces publication of RX-3117 preclinical data theflyonthewall.com
08:00AM  InPlay: Rexahn Pharmaceuticals reports publication of preclinical data for RX-3117; Phase I clinical study in cancer patients with solid tumors anticipated to begin Q4 2013 Briefing.com
08:00AM  Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 Business Wire
12-Sep-13 08:03AM  InPlay: Rexahn Pharmaceuticals awarded patent in Europe for cancer drug Archexin Briefing.com
08:00AM  Rexahn Awarded Patent in Europe for Cancer Drug Archexin┬« Business Wire
05-Sep-13 05:06PM  Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble at Seeking Alpha
08:00AM  Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 Business Wire
04-Sep-13 08:03AM  InPlay: Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update; Fortified balance sheet to fund initiation of three clinical trials in 2013 with data expected in 2014 Briefing.com
08:03AM  InPlay: Rexahn Pharmaceuticals provides a clinical development and financial update; fortified balance sheet to fund initiation of three clinical trials in 2013 with data expected in 2014 Briefing.com
08:00AM  Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update Business Wire
30-Aug-13 10:40AM  Teva-Rexahn Deal Terminated Zacks
29-Aug-13 04:21PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclo EDGAR Online -7.50%
28-Aug-13 09:01AM  InPlay: Rexahn Pharmaceuticals Announces Teva (TEVA) will not Exercise its Option to License RX-3117 Briefing.com -16.67%
09:00AM  Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 Business Wire
20-Aug-13 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials EDGAR Online Financials
12-Aug-13 04:13PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07-Aug-13 08:00AM  Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors Business Wire
05-Aug-13 06:34PM  Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value at Seeking Alpha +7.41%
24-Jul-13 10:20AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure EDGAR Online -6.78%
09:05AM  InPlay: Rexahn Pharmaceuticals announces ~ $5.7 mln direct offering; co agreed to sell aggregate of 11.4 mln shares of its common stock and warrants exercisable for up to ~ 3,990,000 additional shares of its common stock Briefing.com
09:00AM  Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering Business Wire
18-Jul-13 01:58PM  Rexahn Redesigns Cancer Superdrug Taxotere at Seeking Alpha
17-Jul-13 08:06AM  InPlay: Rexahn Pharmaceuticals in-licenses breakthrough oncology drug delivery platform Briefing.com
08:00AM  Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform Business Wire
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system disorders, sexual dysfunction, and other medical needs. Its clinical stage oncology candidates comprise Archexin, an inhibitor of the protein kinase Akt-1, which has completed a Phase IIa clinical trial for the treatment of pancreatic cancer, as well as is focusing on initiating Phase IIa clinical trials for chemo-resistant solid tumors and hematological malignancies; RX-3117, which has completed an exploratory Phase I clinical study in humans with therapeutic potential in a range of cancers, including colon, lung, and pancreatic cancer; and RX-5902, a small molecule that inhibits the phosphorylation of p68 RNA helicase and focuses on initiating Phase I clinical trials. The company's pre-clinical pipeline consist of RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, nano-polymer anticancer. It has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. The company is based in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McIntosh David MDirectorApr 14Option Exercise0.80125,000100,000125,000Apr 16 04:18 PM